Literature DB >> 33274617

Gynecological cancers and the global COVID-19 pandemic

Ibrahim Alkatout1, Mojgan Karimi-Zarchi2, Leila Allahqoli3.   

Abstract

Coronavirus disease-2019 (COVID-19) has reduced the availability of health resources which will affect treatment of gynecological cancers. The present study aimed to provide a treatment protocol for patients with gynecological cancers during the global COVID-19 pandemic. International databases with keywords of COVID-19; Severe Acute Respiratory Syndrome; Middle East Respiratory Syndrome; gynecologic cancer; cervical cancer; and vaginal cancer, vulvar cancer, ovarian cancer, endometrial cancer, tumor, elective surgery, chemotherapy, radiotherapy, cancer, guideline, guidance, women, management, outpatient clinic visits, and triage were comprehensively searched. All the obtained guidelines were studied and the contents were summarized. During the COVID-19 pandemic, early stage endometrial cancer was preferably treated with hormone therapy while radiotherapy was given in preference in later stages. Cervical intraepithelial neoplasia 3 and high-grade squamous intraepithelial lesions should be treated immediately after diagnosis using at least a loop electrosurgical excision procedure while any major surgery should be postponed by 10-12 weeks. In the early stage of cervical cancer, surgery may be delayed by 2-4 weeks, and radiotherapy prescribed for the intervening period. In cases of an ovarian mass with negative tumor markers, no sign of cancer on imaging investigations, no ascites, a low serum CA-125 level, and no papillary projection or vegetation in the base of the cyst, the patient may be given hormone therapy for 2-3 months. In cases of newly diagnosed confirmed ovarian cancers, surgery should be performed as early as possible (maximum: 2-3 weeks). Vulvar and vaginal cancers can be treated within 10-12 weeks of diagnosis, but radiotherapy should be given in preference in this situation. A molar pregnancy is an oncological emergency for which a suction curettage is mandatory; the patient must be monitored for metastases. Information concerning the choice between open or laparoscopic surgery is limited. Given that any patient may be an asymptomatic carrier of the coronavirus, major surgery should be preceded by chest computerized tomography, with and without contrast medium, in order to detect lung lesions. Evidence concerning these recommendations is limited because of the novel and unknown nature of the COVID-19 pandemic. Furthermore, data pertaining to ethical debates about delayed treatment and treatment approaches deviating from current guidelines are also limited.

Entities:  

Keywords:  COVID-19; chemotherapy; elective surgery; gynecological cancer; oncology; radiotherapy

Year:  2020        PMID: 33274617     DOI: 10.4274/jtgga.galenos.2020.2020.0119

Source DB:  PubMed          Journal:  J Turk Ger Gynecol Assoc        ISSN: 1309-0380


  6 in total

Review 1.  Radiotherapy based management during Covid-19 pandemic - A systematic review of presented consensus and guidelines.

Authors:  Zahra Siavashpour; Neda Goharpey; Mosayyeb Mobasheri
Journal:  Crit Rev Oncol Hematol       Date:  2021-06-30       Impact factor: 6.312

Review 2.  Has COVID-19 Affected Cancer Screening Programs? A Systematic Review.

Authors:  Ibrahim Alkatout; Matthias Biebl; Zohre Momenimovahed; Edward Giovannucci; Fatemeh Hadavandsiri; Hamid Salehiniya; Leila Allahqoli
Journal:  Front Oncol       Date:  2021-05-17       Impact factor: 6.244

Review 3.  Proportion of hematological cancer patients with SARS-CoV-2 infection during the COVID-19 pandemic: A systematic review and meta-analysis.

Authors:  Mohammadali Jafari; Seyed Alireza Dastgheib; Farzad Ferdosian; Hamid Mirjalili; Hossein Aarafi; Mahmood Noorishadkam; Mahta Mazaheri; Hossein Neamatzadeh
Journal:  Hematol Transfus Cell Ther       Date:  2021-12-15

4.  Changes in gynecologic and breast cancer diagnoses during the first wave of the COVID-19 pandemic: analysis from a tertiary academic gyneco-oncological center in Germany.

Authors:  Till Kaltofen; Friederike Hagemann; Nadia Harbeck; Rachel Wuerstlein; Bernd Peter Kost; Alexander Burges; Sven Mahner; Fabian Trillsch
Journal:  Arch Gynecol Obstet       Date:  2021-09-07       Impact factor: 2.344

Review 5.  Impact of COVID-19 on cancer screening: a global perspective.

Authors:  Leila Allahqoli; Afrooz Mazidimoradi; Hamid Salehiniya; Ibrahim Alkatout
Journal:  Curr Opin Support Palliat Care       Date:  2022-07-18       Impact factor: 2.265

6.  Treatment delay and treatment pattern modifications among epithelial ovarian cancer patients during the COVID-19 pandemic: A retrospective cohort study.

Authors:  Vinicius Cesar Moterani; Nino Jose Wilson Moterani; Francisco Jose Candido Dos Reis
Journal:  J Surg Oncol       Date:  2022-08-05       Impact factor: 2.885

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.